Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bayer scientists design new hypoglycemic and hypolipidemic agents

Nov. 28, 2003

PROTERM trial evaluates Prochieve for prevention of preterm delivery

Nov. 27, 2003

Final pivotal study of exenatide reports positive results

Nov. 27, 2003

Diamyd increases levels of C-peptide in diabetes patients

Nov. 27, 2003

Cholestagel recommended for approval in E.U.

Nov. 26, 2003

Climara Pro receives FDA approval

Nov. 26, 2003

Merck researchers identify new CB1 modulators for obesity and other uses

Nov. 25, 2003

Merck & Co. discontinues phase III program for MK-767

Nov. 25, 2003

PPD and Syrrx to develop orally delivered DP4 inhibitors

Nov. 25, 2003

Encouraging preliminary results from rat carcinogenicity study of Preos

Nov. 24, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...